rs864622007
|
|
A |
0.830 |
GeneticVariation |
CLINVAR |
|
|
|
rs864622007
|
|
|
0.830 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852564
|
|
A |
0.800 |
CausalMutation |
CLINVAR |
|
|
|
rs137852564
|
|
|
0.800 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852578
|
|
|
0.800 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852593
|
|
|
0.740 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852581
|
|
|
0.720 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852571
|
|
|
0.710 |
GeneticVariation |
UNIPROT |
|
|
|
rs1340026226
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852567
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852580
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852582
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852583
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852584
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852591
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs138454018
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs78686797
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs868669253
|
|
|
0.700 |
GeneticVariation |
UNIPROT |
|
|
|
rs137852593
|
|
|
0.740 |
GeneticVariation |
BEFREE |
R726L androgen receptor mutation is uncommon in prostate cancer families in the united states.
|
12539229 |
2003 |
rs137852593
|
|
|
0.740 |
GeneticVariation |
BEFREE |
R726L substitution in the hormone binding region of androgen receptor was found in 1 prostate cancer family but no previously uncharacterized germline mutations were detected.
|
14665948 |
2004 |
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A prostate cancer mouse model was generated by selectively mutating the AR threonine 877 into alanine in prostatic epithelial cells through Cre-ERT2-mediated targeted somatic mutagenesis.
|
21383160 |
2011 |
rs976306779
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated.
|
15474988 |
2005 |
rs1057519864
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A missense mutation in the ligand-binding domain of the androgen receptor F876L confers resistance to the second-generation antiandrogens enzalutamide and ARN-509 in preclinical models of AR function and prostate cancer and is detected in plasma DNA from ARN-509-treated patients with progressive disease.
|
23779130 |
2013 |
rs137852578
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A total of four human prostate cancer cell models were examined: LNCaP (T877A mutant AR), 22Rv1 (H874Y mutant AR), LAPC4 (wild-type AR), and VCaP (wild-type AR).
|
23813737 |
2013 |
rs139756052
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additional studies will be required to define the frequency and contribution of the AR (A1675T) allele to early-onset and/or familial PCa in African Americans.
|
20173765 |
2010 |